Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.
Clinica Medica 3, Department of Medicine, University of Padova, Via Giustiniani 2, 35128, Padova, Italy. paola.fioretto@unipd.it.
Paola
P
Fioretto
AstraZeneca, Gothenburg, Mölndal, Sweden.
Bergur V
BV
Stefansson
AstraZeneca, Gothenburg, Mölndal, Sweden.
Eva
E
Johnsson
AstraZeneca, Wilmington, Delaware, USA.
Valerie A
VA
Cain
AstraZeneca, Gothenburg, Mölndal, Sweden.
C David
CD
Sjöström
D000419:Albuminuria / Q000378:metabolism / Q000517:prevention & control*; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy* / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D005919:Glomerular Filtration Rate; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D016896:Treatment Outcome
D001559:Benzhydryl Compounds; D005960:Glucosides; C529054:dapagliflozin
Albuminuria; Dapagliflozin; Renal impairment; SGLT2 inhibition; Type 2 diabetes